中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

超声剪切波频散成像对代偿期肝硬化高风险食管胃静脉曲张的诊断价值

王佳音 周洪雨 李庭红 赵蕾 徐佰国 尹伟利 王芳 梁静 经翔 向慧玲

引用本文:
Citation:

超声剪切波频散成像对代偿期肝硬化高风险食管胃静脉曲张的诊断价值

DOI: 10.3969/j.issn.1001-5256.2022.07.018
基金项目: 

天津2019科技重大专项与工程重大疾病防治科技重大专项 (19ZXDBSY00030)

伦理学声明:本研究于2019年12月27日经由天津市第三中心医院伦理委员会审批,批号为IRB2019-022-02,所有患者都签订了知情同意书。
利益冲突声明:本研究不存在研究者、伦理委员会成员、受试者监护人以及与公开研究成果有关的利益冲突。
作者贡献声明:王佳音负责数据收集,统计分析及论文写作;周洪雨、赵蕾负责对文章内容进行批判性审阅;徐佰国参与文章统计分析;李庭红、尹伟利、王芳、梁静负责数据收集,对文章内容进行批判性审阅;经翔负责本研究设计及实施研究;向慧玲负责本研究设计及论文审核。
详细信息
    通信作者:

    向慧玲,huilingxiang@163.com

Value of ultrasonic shear-wave dispersion imaging in diagnosis of high-risk esophageal and gastric varices in compensated cirrhosis

Research funding: 

Tianjin Science and Technology Major Project and Critical Disease Prevention and Control Project 2019 (19ZXDBSY00030)

More Information
  • 摘要:   目的  探讨佳能二维超声剪切波弹性成像(SWE)及频散成像(SWD)在诊断代偿期肝硬化高风险食管胃静脉曲张中的临床价值。  方法  选取2020年2月—2021年2月就诊于天津市第三中心医院接受电子胃镜检查的各种病因代偿期肝硬化患者58例,采用佳能Aplio i800彩色超声仪同期检查肝脏SWE及SWD。以胃镜结果将患者分为高风险食管胃静脉曲张(HREGV)组(n=22)及非高风险食管胃静脉曲张(NHREGV)组(n=36)。正态分布的计量资料两组间比较采用独立样本t检验,非正态分布的计量资料两组间比较采用Mann-Whitney U非参数检验。计数资料两组间比较采用χ2检验。采用多因素logistic回归分析筛选预测肝硬化高风险食管胃静脉曲张的无创指标。采用受试者工作特征曲线分析肝脏SWD及SWE对高风险食管静脉曲张的临床诊断价值。  结果  HREGV组与NHREGV组相比,SWD(t=-3.84,P<0.001)、病因(χ2=9.67,P=0.022)、TBil(Z=-2.00,P=0.045)脾脏直径(t=-2.44,P=0.018)、门静脉直径(Z=-1.96, P=0.005)差异均有统计学意义。代偿期肝硬化患者肝脏SWD平均(15.17±2.45) m·s-1·kHz-1,其中HREGV组肝脏SWD为(16.59±2.66)m·s-1·kHz-1,显著高于NHREGV组的(14.31±1.86) m·s-1·kHz-1(t=-3.84,P<0.001);HREGV组与NHREGV组的SWE差异无统计学意义(Z=-1.21, P=0.223)。SWD为代偿期肝硬化患者发生HREGV的独立危险因素(OR=1.67,95%CI:1.17~2.39,P=0.005)。SWD诊断HREGV的曲线下面积(AUC)为0.786,最佳临界值为15.35 m·s-1·kHz-1,特异度80.56%,敏感度81.82%;SWE诊断HREGV的AUC为0.596,特异度52.78%,敏感度68.18%,最佳临界值为9.25 kPa。  结论  佳能Aplio i800彩色超声测定的SWD有望作为一种新的无创检测方法,在一定程度上预测代偿期肝硬化患者HREGV的存在,SWE则诊断价值有限。

     

  • 图  1  四视图模型

    注:包括剪切波速度图、剪切波到达时间轮廓(传播图)、超声图像、剪切波频散斜率图。

    Figure  1.  Quad-view mode

    图  2  肝脏SWE/SWD诊断代偿期肝硬化患者HREGV的ROC曲线

    Figure  2.  ROC curve of liver SWE/SWD diagnoses HREGV in patients with compensated cirrhosis

    表  1  NHREGV组与HREGV组一般资料比较

    Table  1.   General information of patients in NHREGV group and HREGV group

    指标 总人群(n=58) NHREGV组(n=36) HREGV组(n=22) 统计值 P
    年龄(岁) 53.48±10.91 54.67±10.15 51.55±12.05 t=1.06 0.295
    性别[例(%)] χ2=0.91 0.340
      男 35(60.34) 20(55.56) 15(68.18)
      女 23(39.66) 16(44.44) 7(31.82)
    病因[例(%)] χ2=9.67 0.022
      乙型肝炎 39(67.24) 29(80.56) 10(45.45)
      丙型肝炎 7(12.07) 4(11.11) 3(13.64)
      ALD 5(8.62) 1(2.78) 4(18.18)
      其他 7(12.07) 2(5.56) 5(22.73)
    CTP分级[例(%)] χ2=1.11 0.292
      A 55(94.83) 35(97.22) 20(90.91)
      B 3(5.17) 1(2.78) 2(9.09)
    ALT(U/L) 28.00(11.00~101.70) 30.00(11.00~89.00) 24.00(15.00~101.70) Z=-0.34 0.728
    AST(U/L) 24.0(14.0~184.2) 26.0(14.0~15.0) 29.0(15.0~184.2) Z=-1.33 0.184
    TBil(μmol/L) 18.95(7.60~80.80) 16.10(7.60~80.80) 19.80(12.00~66.60) Z=-2.00 0.045
    SWD(m·s-1·kHz-1) 15.17±2.45 14.31±1.86 16.59±2.66 t=-3.84 <0.001
    SWE(kPa) 9.45(4.70~34.20) 9.20(4.70~34.20) 10.45(5.80~19.00) Z=-1.21 0.223
    脾脏直径(mm) 122.62±23.53 116.82±20.68 131.85±25.27 t =-2.44 0.018
    门静脉直径(mm) 12.4(8.4~23.8) 12.0(8.4~16.0) 13.0(10.0~23.8) Z=-1.96 0.005
    注:ALD,酒精性肝病。
    下载: 导出CSV

    表  2  代偿期肝硬化患者HREGV无创指标的logistic分析

    Table  2.   Logistic analysis of HREGV non-invasive indicators in patients with compensated cirrhosis

    指标 单因素分析 多因素分析
    OR(95%CI) P OR(95%CI) P
    年龄(岁) 0.97(0.927~1.023) 0.292
    性别
      男 1.00
      女 0.58(0.19~1.77) 0.342
    病因
      乙型肝炎 1.00
      丙型肝炎 2.18(0.41~11.45) 0.359 0.34(0.03~3.55) 0.366
      ALD 11.60(1.16~116.42) 0.037 5.65(0.41~77.50) 0.200
      其他 7.25(1.21~43.44) 0.030 4.11(0.39~42.88) 0.240
    CTP分级
      A 1.00
      B 3.50(0.30~41.07) 0.319
    ALT(U/L) 1.01(0.98~1.03) 0.701
    AST(U/L) 1.01(0.99~1.03) 0.229
    TBil(μmol/L) 1.03(0.99~1.08) 0.174
    SWE(kPa) 1.02(0.91~1.13) 0.789
    SWD(m·s-1·kHz-1) 1.64(1.19~2.26) 0.003 1.67(1.17~2.39) 0.005
    脾脏直径(mm) 1.03(1.00~1.06) 0.025 1.03(0.99~1.07) 0.101
    门静脉直径(mm) 1.34(0.99~1.80) 0.057 1.18(0.82~1.71) 0.376
    下载: 导出CSV

    表  3  肝脏SWD/SWE诊断代偿期肝硬化患者HREGV的ROC分析

    Table  3.   ROC analysis of liver SWD/SWE diagnoses HREGV in patients with compensated cirrhosis

    指标 AUC 95%CI 阈值 特异度(%) 敏感度(%) 阳性预测值(%) 阴性预测值(%)
    SWE(kPa) 0.596 0.447~0.745 9.25 52.78 68.18 59.10 62.41
    SWD(m·s-1·kHz-1) 0.786 0.655~0.917 15.35 80.56 81.82 80.83 81.58
    下载: 导出CSV
  • [1] de FRANCHIS R, Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63(3): 743-752. DOI: 10.1016/j.jhep.2015.05.022.
    [2] Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Gastroenterology, Chinese Medical Association, Chinese Society of Endoscopy, Chinese Medical Association. Guidelines for the diagnosis and treatment of esophageal and gastric variceal bleeding in cirrhotic portal hypertension[J]. J Clin Hepatol, 2016, 32(2): 203-219. DOI: 10.3969/j.issn.1001-5256.2016.02.002.

    中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会内镜学分会. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]. 临床肝胆病杂志, 2016, 32(2): 203-219. DOI: 10.3969/j.issn.1001-5256.2016.02.002.
    [3] GARCIA-TSAO G, ABRALDES JG, BERZIGOTTI A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases[J]. Hepatology, 2017, 65(1): 310-335. DOI: 10.1002/hep.28906.
    [4] SHIHA G, IBRAHIM A, HELMY A, et al. Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: A 2016 update[J]. Hepatol Int, 2017, 11(1): 1-30. DOI: 10.1007/s12072-016-9760-3.
    [5] MANATSATHIT W, SAMANT H, KAPUR S, et al. Accuracy of liver stiffness, spleen stiffness, and LS-spleen diameter to platelet ratio score in detection of esophageal varices: Systemic review and meta-analysis[J]. J Gastroenterol Hepatol, 2018, 33(10): 1696-1706. DOI: 10.1111/jgh.14271.
    [6] SUGIMOTO K, MORIYASU F, OSHIRO H, et al. Viscoelasticity measurement in rat livers using shear-wave US elastography[J]. Ultrasound Med Biol, 2018, 44(9): 2018-2024. DOI: 10.1016/j.ultrasmedbio.2018.05.008.
    [7] LEE DH, CHO EJ, BAE JS, et al. Accuracy of two-dimensional shear wave elastography and attenuation imaging for evaluation of patients with nonalcoholic steatohepatitis[J]. Clin Gastroenterol Hepatol, 2021, 19(4): 797-805. e7. DOI: 10.1016/j.cgh.2020.05.034.
    [8] TANG Y, KONG W, ZHAO J, et al. Can viscoelasticity measurements obtained through shear-wave US elastography be used to monitor hepatic ischemia-reperfusion injury and treatment response? An animal study[J]. Ultrasound Med Biol, 2020, 46(9): 2464-2471. DOI: 10.1016/j.ultrasmedbio.2020.04.021.
    [9] Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.

    中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
    [10] JIANG SL, XIONG JB, LOU X, et al. Influence of endoscopic dense ligation combined with sclerosing agent on hepatic synthesis function in treatment of severe esophageal and gastric varices in liver cirrhosis[J]. Clin J Med Offic, 2020, 48(9): 1097-1098. DOI: 10.16680/j.1671-3826.2020.09.38.

    蒋树林, 熊加彬, 娄晓, 等. 内镜下密集套扎结合硬化剂治疗肝硬化食管胃重度静脉曲张对患者肝合成功能影响[J]. 临床军医杂志, 2020, 48(9): 1097-1098. DOI: 10.16680/j.1671-3826.2020.09.38.
    [11] SHI XJ, SHEN JH, NIU HM, et al. Clinical effect and prognostic value of endoscopic ultrasound-guided treatment of esophageal varices in liver cirrhosis[J]. Chin J Gerontol, 2021, 41(8): 1634-1638. DOI: 10.3969/j.issn.1005-9202.2021.08.021.

    石小静, 申军华, 牛红梅, 等. 超声内镜指导下对肝硬化并发食管静脉曲张内镜下治疗的临床疗效及预后价值[J]. 中国老年学杂志, 2021, 41(8): 1634-1638. DOI: 10.3969/j.issn.1005-9202.2021.08.021.
    [12] QI X, BERZIGOTTI A, CARDENAS A, et al. Emerging non-invasive approaches for diagnosis and monitoring of portal hypertension[J]. Lancet Gastroenterol Hepatol, 2018, 3(10): 708-719. DOI: 10.1016/S2468-1253(18)30232-2.
    [13] WANG L, FENG Y, MA X, et al. Diagnostic efficacy of noninvasive liver fibrosis indexes in predicting portal hypertension in patients with cirrhosis[J]. PLoS One, 2017, 12(8): e0182969. DOI: 10.1371/journal.pone.0182969.
    [14] DENG H, QI X, ZHANG T, et al. Supersonic shear imaging for the diagnosis of liver fibrosis and portal hypertension in liver diseases: A meta-analysis[J]. Expert Rev Gastroenterol Hepatol, 2018, 12(1): 91-98. DOI: 10.1080/17474124.2018.1412257.
    [15] LI Q, WANG R, GUO X, et al. Contrast-enhanced CT may be a diagnostic alternative for gastroesophageal varices in cirrhosis with and without previous endoscopic variceal therapy[J]. Gastroenterol Res Pract, 2019, 2019: 6704673. DOI: 10.1155/2019/6704673.
    [16] QI X, AN W, LIU F, et al. Virtual hepatic venous pressure gradient with CT angiography (CHESS 1601): A prospective multicenter study for the noninvasive diagnosis of portal hypertension[J]. Radiology, 2019, 290(2): 370-377. DOI: 10.1148/radiol.2018180425.
    [17] ABRALDES JG, BUREAU C, STEFANESCU H, et al. Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The "Anticipate" study[J]. Hepatology, 2016, 64(6): 2173-2184. DOI: 10.1002/hep.28824.
    [18] Chinese Foundation for Hepatitis Prevention and Control, Chinese Society of Infectious Disease, Chinese Society of Hepatology and Chinese Medical Association Liver Disease Committee of Chinese Research Hospital Association. Consensus on clinical application of transient alastography detecting liver fibrosis: A 2018 update[J]. Chin J Hepatol, 2019, 27(3): 182-191. DOI: 10.3760/cma.j.issn.1007-3418.2019.03.004.

    中国肝炎防治基金会, 中华医学会感染病学分会, 中华医学会肝病学分会和中国研究性医院学会肝病专业委员会. 瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版)[J]. 中华肝脏病杂志, 2019, 27(3): 182-191. DOI: 10.3760/cma.j.issn.1007-3418.2019.03.004
    [19] XIE LT, YAN CH, ZHAO QY, et al. Quantitative and noninvasive assessment of chronic liver diseases using two-dimensional shear wave elastography[J]. World J Gastroenterol, 2018, 24(9): 957-970. DOI: 10.3748/wjg.v24.i9.957.l.
    [20] Panel of Elastography Assessment of Liver Fibrosis, Study Group of Interventional Ultrasound, Society of Ultrasound in Medicine of Chinese Medical Association. Guidelines for clinical application of two-dimensional shear wave elastography in assessment of liver fibrosis in chronic hepatitis B[J]. J Clin Hepatol, 2018, 34(2): 255-261. DOI: 10.3969/j.issn.1001-5256.2018.02.008.

    中华医学会超声医学分会介入超声学组弹性成像评估肝纤维化专家组. 二维剪切波弹性成像评估慢性乙型肝炎肝纤维化临床应用指南[J]. 临床肝胆病杂志, 2018, 34(2): 255-261. DOI: 10.3969/j.issn.1001-5256.2018.02.008.
    [21] CHEN S, URBAN MW, PISLARU C, et al. Liver elasticity and viscosity quantification using shearwave dispersion ultrasound vibrometry (SDUV)[J]. Annu Int Conf IEEE Eng Med Biol Soc, 2009, 2009: 2252-2255. DOI: 10.1109/IEMBS.2009.5334992.
    [22] LEE DH, CHO EJ, BAE JS, et al. Accuracy of two-dimensional shear wave elastography and attenuation imaging for evaluation of patients with nonalcoholic steatohepatitis[J]. Clin Gastroenterol Hepatol, 2021, 19(4): 797-805. e7. DOI: 10.1016/j.cgh.2020.05.034.
    [23] LEE DH, LEE JY, BAE JS, et al. Shear-wave dispersion slope from US shear-wave elastography: Detection of allograft damage after liver transplantation[J]. Radiology, 2019, 293(2): 327-333. DOI: 10.1148/radiol.2019190064.
    [24] NIGHTINGALE KR, ROUZE NC, ROSENZWEIG SJ, et al. Derivation and analysis of viscoelastic properties in human liver: Impact of frequency on fibrosis and steatosis staging[J]. IEEE Trans Ultrason Ferroelectr Freq Control, 2015, 62(1): 165-175. DOI: 10.1109/TUFFC.2014.006653.
    [25] DEFFIEUX T, GENNISSON JL, BOUSQUET L, et al. Investigating liver stiffness and viscosity for fibrosis, steatosis and activity staging using shear wave elastography[J]. J Hepatol, 2015, 62(2): 317-324. DOI: 10.1016/j.jhep.2014.09.020.
    [26] VIZZUTTI F, ARENA U, ROMANELLI RG, et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis[J]. Hepatology, 2007, 45(5): 1290-1297. DOI: 10.1002/hep.21665.
    [27] JEON SK, LEE JM, JOO I, et al. Two-dimensional shear wave elastography with propagation maps for the assessment of liver fibrosis and clinically significant portal hypertension in patients with chronic liver disease: A prospective study[J]. Acad Radiol, 2020, 27(6): 798-806. DOI: 10.1016/j.acra.2019.08.006.
    [28] YOU MW, KIM KW, PYO J, et al. A Meta-analysis for the diagnostic performance of transient elastography for clinically significant portal hypertension[J]. Ultrasound Med Biol, 2017, 43(1): 59-68. DOI: 10.1016/j.ultrasmedbio.2016.07.025.
    [29] GILLIGAN LA, TROUT AT, BENNETT P, et al. Repeatability and agreement of shear wave speed measurements in phantoms and human livers across 6 ultrasound 2-dimensional shear wave elastography systems[J]. Invest Radiol, 2020, 55(4): 191-199. DOI: 10.1097/RLI.0000000000000627.
    [30] DENG H, QI X, ZHANG T, et al. Supersonic shear imaging for the diagnosis of liver fibrosis and portal hypertension in liver diseases: A meta-analysis[J]. Expert Rev Gastroenterol Hepatol, 2018, 12(1): 91-98. DOI: 10.1080/17474124.2018.1412257.
    [31] BERZIGOTTI A. Non-invasive evaluation of portal hypertension using ultrasound elastography[J]. J Hepatol, 2017, 67(2): 399-411. DOI: 10.1016/j.jhep.2017.02.003.
    [32] SHARMA P, KIRNAKE V, TYAGI P, et al. Spleen stiffness in patients with cirrhosis in predicting esophageal varices[J]. Am J Gastroenterol, 2013, 108(7): 1101-1107. DOI: 10.1038/ajg.2013.119.
  • 加载中
图(2) / 表(3)
计量
  • 文章访问数:  451
  • HTML全文浏览量:  240
  • PDF下载量:  55
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-10-30
  • 录用日期:  2021-12-17
  • 出版日期:  2022-07-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回